China

Aktuelle eAlerts

•  

  10/09/2024

  International

  CMS Annual Review of English Construction Law Developments: An International Perspective

  We are pleased to announce the publication of the 2024 edition of our internationally focused Annual Review of English Construction Law Developments. The Annual Review summarises key developments in English construction law over the previous calendar year including developments in related common law jurisdictions. The publication has been prepared with our international clients in mind and aims to provide a greater degree of background and analysis than our regular Law-Now alert service.This year’s edition has a strong focus on exclusion and limitation clauses, with more than half of the...

  Mehr
•  

  10/09/2024

  APAC region

  No room for ignorance: Singapore High Court clarifies directors’ duties

  Inter-Pacific Petroleum Pte Ltd (in liquidation) v Goh Jin Hian [2024] SGHC 178 In what could be seen as a wake-up call, the High Court of Singapore clarified the scope of director’s duties in Singapore, emphasizing the minimum standard of care required.BackgroundInter-Pacific Petroleum Pte Ltd (“IPP”), a petrochemical and ship bunkering company, was placed under judicial management in September 2019, and later liquidated in March 2021. IPP had borrowed over US$150 million to fund its cargo trading and bunkering transactions. These sums were never repaid to the banks. IPP’s...

  Mehr
•  

  10/09/2024

  China

  China’s opens its healthcare sector to more foreign investment

  On 8 September 2024, the China’s Ministry of Commerce (MOFCOM), the National Health Commission (NHC) and the National Medical Products Administration (NMPA) issued a joint Circular on the pilot programmes to further open the republic’s healthcare sector to foreign investors. The Circular outlines two major initiatives: the establishment of wholly foreign-owned hospitals in select regions, including Beijing and Shanghai, and the engagement of foreign-invested enterprises (FIEs) in biotechnology within designated free trade zones (FTZs).Key points of the Circular1. Biotechnology development...

  Mehr
•  

  05/09/2024

  China

  China enters new regulatory era with release of first draft Medical Devices Administration Law for Public Comment

  On 28 August 2024, China’s National Medical Products Administration (NMPA) released the draft of the Medical Devices Administration Law of the People's Republic of China for public comment with the deadline for feedback set for 28 September 2024.Unlike pharmaceutical products, for over two decades medical devices have not been governed by a national-level law from the National People's Congress, such as the Drug Administration Law, but by an administrative regulation, the Regulation on the Supervision and Administration of Medical Devices (i.e. "Medical Device Regulation"), and various separate...

  Mehr
•  

  14/08/2024

  China

  Draft anti-monopoly guidelines in the pharma sector released by China SAMR

  On 9 August 2024, China’s State Administration for Market Regulation (SAMR) released a draft of the Antimonopoly Guidelines in the Field of Pharmaceuticals for public comments. These Guidelines are designed to provide clearer guidance on antitrust enforcement and compliance for operators across the entire pharmaceutical industry.Key elements of the Guidelines1. Expanded scope of applicationThe Guidelines expand and refine the scope of antitrust regulation within the pharmaceutical sector, building on the Anti-monopoly Law of the People's Republic of China (AML) and the previously issued Antitrust...

  Mehr
•  

  12/08/2024

  China

  Corporate Social Credit System Regulatory Update - Top 20 FAQ

  The following shows a selection of frequently answered questions in conjunction with China’s Corporate Social Credit System (“CSCS”) and reflects the most recent regulatory developments until June 2024.Regulatory Purpose of CSCSQ1:  What is the regulatory purpose of China’s Corporate Social Credit System?A1:  The regulatory purpose of CSCS is to incentivize those companies, which are compliant with Chinese laws and to punish those, which are not compliant. The Chinese regulator has developed various tools for punishing and awarding certain conducts of companies...

  Mehr